RSV vaccines

Price for one auto-disable (AD) syringe and needle 

• As of October 2025, the UNICEF procurement price for 2026 ranges from US$ 0.023 to US$ 0.046, depending on supplier and product.^{Go to footnote 11} 
• The 2026 PAHO Revolving Fund for Access to Vaccines price ranges from US$ 0.03 to US$ 0.04, depending on supplier and product.^{Go to footnote 22} 
   

Price for one 5-litre safety box  

• The UNICEF procurement price for 2026 ranges from US$ 0.375 to US$ 0.860, depending on supplier and product.^{Go to footnote 33} 
• The 2026 PAHO Revolving Fund for Access to Vaccines price ranges from US$ 0.41 to US$ 0.47, depending on supplier and product.^{Go to footnote 22} Each 5-litre safety box can hold around 100 syringes.
   

Syringe price per dose is estimated to be equal for both the maternal vaccine and the infant mAb. The safety box price per dose is also estimated to be the same between both products. 

For prefilled-syringe mAb presentations, separate needle/syringe procurement depends on presentation; safety box use remains relevant.

The country-reported prices per dose for 2025 for maternal RSV Pre-F vaccine in HIC and UMICs ranged between US$ 49.0 and US$245.9.^{Go to footnote 44}

The 2025 price reported by the PAHO Revolving Fund for the maternal RSV Pre-F vaccine for participating countries was US$ 49 per dose.^{Go to footnote 55}

As of June 2026, price per dose for the maternal vaccine in the United States of America ranges between US$ 240 and US$ 319. The price per dose for the monoclonal antibody ranges between US$ 422 and US$ 595.^{Go to footnote 66} 

The Gates Foundation provided Pfizer with a grant to support the development of an affordable multidose vial for delivery of the RSV vaccine candidate in lower-income countries via public sector purchasers, including Gavi. ^{Go to footnote 77}

Gavi and the manufacturer of the RSV Pre-F maternal vaccine are working towards sharing a directional price with countries in 2026, subject to final tendering and contracting through UNICEF. All Partners are working towards introducing the RSV multidose vial affordably and in line with other vaccines made available through the Gavi to eligible countries.

The country-reported price range for nirsevimab in 2025 ranged between US$ 258.8 and US$ 320.4.^{Go to footnote 44}

To date, no price commitment for LMICs for any mAb has been made.

Globally, the estimated financial cost per person vaccinated varies between countries. In 2018, the reported cost of delivering a maternal vaccine ranged from US$ 0.55 to US$ 0.64 for LICs, US$ 1.25 to US$ 6.55 for MICs, and US$ 5.76 to US$ 39.87 in HICs.^{Go to footnote 88}

Recent prospective maternal immunization costing studies suggest that the delivery cost (excluding the vaccine price) per dose is similar to that of vaccines for infants and young children, between US$ 0.45 - 1.81 (financial) and US$ 2.01 - 4.49 (economic) in South Asia, and between US$ 1.74 - 3.42 (financial) and US$ 2.21- 6.6 (economic) in sub-Saharan Africa. Key cost drivers include health worker training, social mobilisation, and programme planning.^{Go to footnote 99, Go to footnote 1010, Go to footnote 1111}

The UNICEF financial cost estimate for delivering birth dose vaccines (BCG and the HepB vaccines) is US$ 2.34; this provides an estimate of delivery costs for nirsevimab as a birth dose. In addition to these costs, the direct cost of the vaccines and mAb per dose will need to be included (currently unknown for LMICs).^{Go to footnote 1212}

A study evaluating RSV intervention cost effectiveness in 133 LMICs found that RSV interventions could be cost saving in one-third of countries evaluated and cost-effective in the remaining countries at willingness-to-pay threshold of 0.5 GDP per capita and when the price for the maternal RSV Pre-F vaccines was US$ 3.50 and the price of the mAb was US$ 3.50 per dose, respectively.^{Go to footnote 1313}

Under the anticipated lower prices for maternal RSV Pre-F vaccine, immunization is expected to be more cost-effective than using nirsevimab.^{Go to footnote 1414}

In a cost-effectiveness analysis in the United States of America, when compared with palivizumab, clesrovimab and nirsevimab were estimated to cost US$ 38 655 and US$ 79 912 per QALY, respectively. Results were sensitive to changes in intervention costs, efficacy, and QALY loss due to RSV infection.^{Go to footnote 1515}

Cost–effectiveness varies considerably by several factors, including, the burden of disease, vaccination coverage, vaccine price, delivery costs, delivery approaches, and schedules. Caution is recommended when comparing estimates of cost-effectiveness for different interventions evaluated by different methods and in different contexts (e.g., with different concurrent health interventions and standards of care).

Both the maternal vaccines and infant long-acting mAbs were approved in-principle in the 2018 Gavi Vaccine Investment Strategy, subject to specific conditions.^{Go to footnote 1616}

As part of Gavi Strategy 2026-2030 (Gavi 6.0), maternal RSV Pre-F vaccine is supported through the discretionary vaccine budget. All Gavi-eligible countries that have not introduced the maternal RSV vaccination in their national vaccination schedule are eligible for support. A multi-dose vial formulation of the vaccine, now pre-qualified by WHO, will be available via Gavi support.^{Go to footnote 1717}